BE640616A - - Google Patents

Info

Publication number
BE640616A
BE640616A BE640616DA BE640616A BE 640616 A BE640616 A BE 640616A BE 640616D A BE640616D A BE 640616DA BE 640616 A BE640616 A BE 640616A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of BE640616A publication Critical patent/BE640616A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE640616D 1962-12-19 BE640616A (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US245681A US3119742A (en) 1962-12-19 1962-12-19 Method of preparing sustained release pharmaceutical pellets and product thereof

Publications (1)

Publication Number Publication Date
BE640616A true BE640616A (enExample)

Family

ID=22927638

Family Applications (1)

Application Number Title Priority Date Filing Date
BE640616D BE640616A (enExample) 1962-12-19

Country Status (5)

Country Link
US (1) US3119742A (enExample)
BE (1) BE640616A (enExample)
GB (1) GB1030127A (enExample)
IT (1) IT983055B (enExample)
SE (1) SE328670B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
CA1279574C (en) * 1985-04-17 1991-01-29 Jeffrey L. Finnan Process for lubricating water-soluble vitamin powders
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
SE8701479L (sv) * 1987-04-09 1988-10-10 Carbomatrix Ab Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
FI77573C (fi) * 1987-05-08 1989-04-10 Orion Yhtymae Oy Ny konsistens.
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5328697A (en) * 1992-02-10 1994-07-12 Mallinckrodt Veterinary, Inc. Compositions and processes for the sustained release of drugs
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
SK13652002A3 (sk) * 2000-03-31 2004-01-08 Pfizer Products Inc. Deriváty piperazínu
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
HUP0301442A3 (en) * 2000-10-19 2007-03-28 Pfizer Prod Inc Bridged piperazine derivatives and pharmaceutical compositions containing them
EE200400023A (et) * 2001-06-20 2004-06-15 Pfizer Products Inc. Uued sulfoonhappe derivaadid
CZ2004519A3 (cs) * 2001-10-22 2004-12-15 Pfizer Products Inc. Deriváty piperazinu s účinky antagonisty receptoru CCR1
JP2005530775A (ja) * 2002-05-14 2005-10-13 ファイザー・プロダクツ・インク ジヒドロキシヘキサン酸誘導体、それらの中間体、および製法
CA2484342A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
PA8575901A1 (es) * 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
MXPA05001781A (es) * 2002-08-12 2005-04-25 Pfizer Prod Inc Formas cristalinas de [4-carbamoil -1-(3- fluorobencil)-2, 7-dihidroxi- 7-metil- octil]-amida del acido quinoxalina-2- carboxilico.
OA12929A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Pyrazole derivatives as transforming growth (TGF) inhibitors.
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
AU2003276591A1 (en) * 2002-11-26 2004-06-18 Pfizer Products Inc. Method of treatment of transplant rejection
JP2006509815A (ja) * 2002-12-13 2006-03-23 ファイザー・プロダクツ・インク 新規なリン含有誘導体
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
JP2006517580A (ja) * 2003-02-14 2006-07-27 ファイザー・プロダクツ・インク 抗炎症化合物としてのトリアゾロピリジン
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
MXPA05009245A (es) 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
CA2545192A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
US8461102B2 (en) * 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
CN103917094B (zh) 2011-03-18 2016-11-09 建新公司 葡萄糖基神经酰胺合酶抑制剂
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
CA2844577A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
HK1220184A1 (zh) 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
WO2015061665A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
BR112017002001B1 (pt) 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US12570664B2 (en) 2015-10-16 2026-03-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017294572B2 (en) 2016-07-08 2021-11-04 Chu De Nice 4-anilino-quinoline compounds as anti-cancer agents
EP3735408B1 (en) 2018-01-05 2023-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Substituted halo-quinoline derivatives, method of preparation and applications thereof
US20210347758A1 (en) 2018-10-03 2021-11-11 Tesaro, Inc. Crystalline Forms of Niraparib Freebase
CN118994103A (zh) 2018-10-03 2024-11-22 特沙诺有限公司 尼拉帕利盐
WO2020163244A1 (en) 2019-02-04 2020-08-13 Genzyme Corporation Methods for treating symptoms and disorders associated with lysosomal storage diseases
US12527776B2 (en) 2019-02-04 2026-01-20 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
EP4100009A1 (en) 2020-02-03 2022-12-14 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
TW202241888A (zh) 2020-12-23 2022-11-01 美商健臻公司 氘化群落刺激因子-1受體(csf-1r)抑制劑
WO2023196640A1 (en) 2022-04-08 2023-10-12 Bioverativ Therapeutics Inc. Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
KR20250106321A (ko) 2022-12-01 2025-07-09 젠자임 코포레이션 강력하거나 중간 수준인 cyp3a4 억제제와 조합한 벤글루스타트
WO2025074120A1 (en) 2023-10-06 2025-04-10 Imperial College Innovations Limited Nanoparticles for extended release drug delivery
WO2025262570A1 (en) 2024-06-17 2025-12-26 Genzyme Corporation Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment
GB202411975D0 (en) 2024-08-14 2024-09-25 Imperial College Innovations Ltd Nanoparticles for extended release drug delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments

Also Published As

Publication number Publication date
SE328670B (enExample) 1970-09-21
DE1492128A1 (de) 1969-08-07
IT983055B (it) 1974-10-31
GB1030127A (en) 1966-05-18
US3119742A (en) 1964-01-28

Similar Documents

Publication Publication Date Title
BE627498A (enExample)
FI41968B (enExample)
BE626612A (enExample)
BE627513A (enExample)
BE620474A (enExample)
BE627977A (enExample)
BE628237A (enExample)
BE627791A (enExample)
BE627962A (enExample)
BE626679A (enExample)
SE328670B (enExample)
BE622733A (enExample)
BE627049A (enExample)
BE627359A (enExample)
BE630733A (enExample)
BE626693A (enExample)
BE617118A (enExample)
BE630590A (enExample)
BE621948A (enExample)
BE627215A (enExample)
BE627650A (enExample)
BE627948A (enExample)
BE624035A (enExample)
BE625612A (enExample)
BE633821A (enExample)